MedTrace Logo

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

NCT00051025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-07-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.

Conditions

  • Non-Hodgkin's Lymphoma
  • Lymphoma, B-cell
  • Lymphoma, Low-grade

Interventions

DRUG

ONTAK

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Elyane Lombardy, M.D. · Ligand Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2001-01-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051025 on ClinicalTrials.gov